Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.63
+0.24 (1.38%)
At close: Aug 14, 2026, 4:00 PM EDT
17.58
-0.05 (-0.28%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Takeda Pharmaceutical Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 4,618,935 | 4,505,720 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 |
Revenue Growth | 3.10% | -1.65% | 7.45% | 5.87% | 12.85% | 11.61% |
Gross Profit Gross Profit Growth | 2,977,720 | 2,886,506 | 3,010,132 | 2,832,257 | 2,774,315 | 2,441,698 |
Operating Income Operating Income Growth | 639,498 | 607,842 | 562,936 | 502,602 | 619,667 | 600,062 |
Net Income Net Income Growth | -163,436 | -152,390 | 107,928 | 144,067 | 317,017 | 230,059 |
Earnings Per Share EPS Growth | -103.52 | -96.75 | 67.23 | 91.16 | 201.94 | 145.87 |
EPS Growth | - | - | -26.25% | -54.86% | 38.44% | -38.96% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
GI GI Growth | 1,454,300 | 1,407,460 | 1,357,022 | 1,216,207 | 1,094,541 |
Rare Diseases Rare Diseases Growth | 772,300 | 762,698 | 752,816 | 688,423 | 639,774 |
PDT PDT Growth | 1,080,500 | 1,057,524 | 1,032,662 | 903,699 | 763,359 |
Oncology Oncology Growth | 606,900 | 580,126 | 560,430 | 462,362 | 438,742 |
Vaccines Vaccines Growth | 62,100 | 59,607 | 55,412 | 50,355 | 78,664 |
Neuroscience Neuroscience Growth | 419,300 | 414,343 | 565,816 | 627,014 | 637,711 |
Other Product Other Product Growth | 223,500 | 223,961 | 257,392 | 315,701 | 372,685 |
Revenue (Total) Revenue (Total) Growth | 4,618,896 | 4,505,700 | 4,581,551 | 4,263,762 | 4,027,478 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 460,982 | 595,054 | 385,113 | 457,800 | 533,530 | 849,695 |
Total Debt Total Debt Growth | 5,536,499 | 5,476,358 | 5,088,590 | 5,463,391 | 4,861,692 | 4,810,649 |
Net Cash (Debt) Net Cash Growth | -5,075,517 | -4,881,304 | -4,703,477 | -5,005,591 | -4,328,162 | -3,960,954 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3214.67 | -3099.12 | -2929.93 | -3167.41 | -2757.02 | -2511.43 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 953,631 | 1,041,431 | 1,057,182 | 716,344 | 977,156 | 1,123,105 |
Capital Expenditures CapEx Growth | -181,901 | -176,003 | -200,795 | -175,420 | -140,657 | -123,252 |
Free Cash Flow Free Cash Flow Growth | 771,730 | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | -15.29% | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 64.47% | 64.06% | 65.70% | 66.43% | 68.88% | 68.41% |
Operating Margin | 13.84% | 13.49% | 12.29% | 11.79% | 15.39% | 16.81% |
Pretax Margin | -2.82% | -3.16% | 3.82% | 1.24% | 9.31% | 8.48% |
Profit Margin | -3.54% | -3.38% | 2.36% | 3.38% | 7.87% | 6.45% |
FCF Margin | 16.71% | 19.21% | 18.69% | 12.69% | 20.77% | 28.02% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 15, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.492 | 200.000 | 196.000 | 188.000 | 180.000 | 180.000 |
Dividend Per Share Growth | -9.35% | 2.04% | 4.25% | 4.44% | 0% | 0% |
Dividend Yield | 2.79% | 6.79% | 9.08% | 9.57% | 9.09% | 11.87% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 15, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 62.54 | 45.57 | 21.33 | 23.57 |
P/FCF Ratio | 11.62 | 10.34 | 7.88 | 12.14 | 8.08 | 5.42 |
PS Ratio | 1.98 | 1.99 | 1.47 | 1.54 | 1.68 | 1.52 |